Terns plans to move to a Phase 2 trial for its TERN-601 small-molecule GLP-1 receptor agonist and will submit the latest data to a coming scientific conference.
MarketWatch.com – Top Stories
Terns plans to move to a Phase 2 trial for its TERN-601 small-molecule GLP-1 receptor agonist and will submit the latest data to a coming scientific conference.
MarketWatch.com – Top Stories